Alimera Sciences Inc - ALIM Net Assets per Single Share

Graphic logo of Alimera Sciences, Inc. (ALIM)

Alimera Sciences (ALIM) is implementing ESG standards in production and optimizing packaging while scaling sales of retinal drugs under the umbrella of a new holding company. This chart of book value per share demonstrates a fundamental trend, where 0.74 serves as the final level mark. Alimera Sciences is developing a unique long-term drug delivery method that replaces frequent injections with a single procedure lasting several years.

Alimera (ALIM): Share Book Value from 07/04/2022 to 09/21/2024

Alimera Sciences Inc - analytical breakdowns and key metrics (ALIM)

- price and consensus price forecast:
Stock Price Alimera|ALIM - Analyst Median Target
- market capitalization data:
Market Value Alimera Sciences, Inc.|ALIM - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share Alimera Sciences|ALIM - Net Asset Value|Market Capitalization to Book Value Ratio alimerasciences.com|ALIM - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Alimera Sciences|ALIM - Long-Term Debt to Capital|Short-Term Debt to Equity Alimera|ALIM - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Alimera Sciences, Inc.
Fundamental company valuation:alimerasciences.com - ALIM
Manufactured products of Alimera

The growth of the current BVPS value reflects the capitalization of the exclusivity of the drug Iluvien and the high margins of the Alimera Sciences (ALIM) business. This indicator is calculated as the ratio of equity minus preferred shares to the total number of shares outstanding, determining the intrinsic value of an investor's stake and the price floor of the asset in a fundamental valuation of the company.

Competitors of Alimera Sciences (ALIM)

Book Value per Share ALC (Alcon Vision)|BLCO: Net Assets per Share|GKOS (Glaukos Corporation) - Net Assets per Single Share|APLS (apellis.com) - Accounting Value per Share|Net Assets per Single Share belitebio.com BLTE|Share Book Value Ocular Therapeutix Inc|Harrow Health (HROW) - Book Value per Share|Accounting Value of a Share Viridian Corp (VRDN)|Book Value per Share LENZ (LENZ Therapeutics, Inc.)|Oculis Pharma - Book Value per Share|Net Assets per Single Share EyePoint Pharmaceuticals, Inc. (EYPT)|KOD: Accounting Value of a Share|ALDX (aldeyra.com) - Net Assets per Single Share|KALA BIO (KALA) - Accounting Value per Share|IRD (Opus Genetics, Inc.) - Book Value per Share|Book Value per Share OKYO Pharma Inc (OKYO)|Adverum Biotechnologies (ADVM) - Accounting Value per Share|Accounting Value of a Share Outlook Therapeutics Inc (OTLK)|CLSD: Book Value per Share|NBY - Net Asset Value per Share|KPRX (Kiora Pharma) - Accounting Value per Share|EYEN - Net Asset Value per Share|Book Value per Share GHSI|OCUP (Ocuphire Pharma Inc) - Net Asset Value per Share|OPT: Net Assets per Single Share